GALP Activators

GALP activators predominantly consist of compounds that can modulate the activity of the galanin family of neuropeptides, especially GALP, by acting on galanin receptors or the interconnected neural systems. Compounds like Galnon and M617 directly target galanin receptors. Specifically, Galnon is a non-peptide galanin receptor agonist that upregulate GALP expression or release through the activation of galanin receptors. M617, on the other hand, is a specific agonist for the galanin receptor 3 (GALR3), which, when activated, can amplify GALP levels or functionality within neural pathways. The complexities of the neural signaling networks involve multiple systems that interact with the galaninergic system. For instance, the neuropeptide Y (NPY) and GALP show interconnected roles in the hypothalamus. Activation of NPY signaling by chemicals can, therefore, exert an impact on GALP levels. In a similar vein, the compound CHPG, a selective mGluR5 agonist, modulates glutamatergic signaling, and can indirectly influence GALP expression in neurons where both mGluR5 and GALP co-exist.

The cannabinoid system offers another entry point to modulate GALP. O-2050, a CB1 cannabinoid receptor agonist, suggests that the endocannabinoid system and the galaninergic system interact, and their activation could upregulate GALP. Furthermore, compounds like NPS 2390, a selective antagonist for the metabotropic glutamate receptor 1 (mGluR1), provide a unique angle of action. By inhibiting mGluR1, this compound can modulate GALP levels in specific neurons, bolstering its signaling. Another intricate network involves the GABAergic and galaninergic systems. DHX, or Dehydroxycorticosterone, modulates GABA(A) receptors. By influencing GABAergic signaling, it can modulate GALP activity, albeit indirectly. Similarly, dopaminergic compounds like SKF 38393 and Rotigotine highlight the interconnectedness of the dopaminergic and galaninergic systems. Enhancing D1 signaling or general dopaminergic signaling through these compounds can impart effects on GALP function. Lastly, Pregnenolone sulfate and Ghrelin demonstrate the broader scope of compounds that, while not directly targeting GALP, can influence its activity due to their roles in overlapping or interconnected cellular pathways.